title: Association of copeptin with myocardial infarct size and myocardial function after ST segment elevation myocardial infarction.
abstract: OBJECTIVE
  To investigate the relationship between circulating plasma copeptin values and infarct size as well as myocardial function at baseline and 4 months after mechanical reperfusion for ST segment elevation myocardial infarction (STEMI).
  
  
  METHODS
  Prospective observational cohort study.
  
  
  METHODS
  University Hospital of Innsbruck.
  
  
  METHODS
  54 patients with acute STEMI.
  
  
  METHODS
  Correlation of plasma copeptin with infarct size as well as left ventricular ejection fraction (LVEF) and remodelling.
  
  
  METHODS
  Participants underwent contrast enhanced cardiac MRI at baseline and 4 months thereafter. Blood samples were drawn 2 days after the onset of symptoms. Copeptin values were determined by an immunofluorescent assay.
  
  
  RESULTS
  Copeptin concentrations (median 10.4 pmol/l, IQR 6.0-14.4) were associated with early and chronic infarct size (r=0.388, p=0.004 at baseline; r=0.385, p=0.011 at follow-up) and inversely related to LVEF at both times (r=-0.484, p<0.001 at baseline; r=-0.461, p<0.001 at follow-up). Patients with adverse remodelling showed higher baseline copeptin values compared to patients without remodelling (p=0.02). Receiver operating characteristic analysis indicated a cut-off value of 16.7 pmol/l for copeptin to best identify patients with future adverse remodelling.
  
  
  CONCLUSIONS
  Increased copeptin values 2 days after STEMI are associated with larger acute and chronic infarct sizes. Moreover, elevated copeptin concentrations at baseline were associated with myocardial function and remodelling 4 months post-STEMI. These findings strengthen the role of copeptin as a biomarker of adverse outcome after STEMI.
authors.affiliation: University Clinic of Internal Medicine III, Cardiology, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Sebastian Johannes
authors.initials: SJ
authors.lastname: Reinstadler
authors.forename: Gert
authors.initials: G
authors.lastname: Klug
authors.forename: Hans-Josef
authors.initials: HJ
authors.lastname: Feistritzer
authors.forename: Agnes
authors.initials: A
authors.lastname: Mayr
authors.forename: Bettina
authors.initials: B
authors.lastname: Harrasser
authors.forename: Johannes
authors.initials: J
authors.lastname: Mair
authors.forename: Kerstin
authors.initials: K
authors.lastname: Bader
authors.forename: Katrin
authors.initials: K
authors.lastname: Streil
authors.forename: Angelika
authors.initials: A
authors.lastname: Hammerer-Lercher
authors.forename: Regina
authors.initials: R
authors.lastname: Esterhammer
authors.forename: Bernhard
authors.initials: B
authors.lastname: Metzler
mesh_terms: D004562:Electrocardiography; D005500:Follow-Up Studies; D006020:Glycopeptides / Q000097:blood*; D006352:Heart Ventricles / Q000473:pathology / Q000503:physiopathology*; D006801:Humans; D019028:Magnetic Resonance Imaging, Cine; D009200:Myocardial Contraction / Q000502:physiology*; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000503:physiopathology; D009206:Myocardium / Q000473:pathology*; D011379:Prognosis; D011446:Prospective Studies; D012720:Severity of Illness Index; D020257:Ventricular Remodeling
chemical_list: D006020:Glycopeptides; C048197:copeptins